Cannabis Science Extracts Kill Cancer Cells In Cancer Patients Being Treated Through Its Licensed Distributor Rockbrook
February 22 2011 - 3:08PM
Business Wire
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech
company developing pharmaceutical cannabis (marijuana derivative)
products, is pleased to announce that numerous patients are
reporting that Cannabis Science extract treatments are killing
cancer cells. Cannabis Science, in conjunction with Rockbrook, its
Colorado-licensed dispensary, consulted with a variety of cancer
patients who were seeking to inform themselves of the current peer
reviewed scientific literature, regarding the historical use of
cannabis to treat "tumors”. Unlike most conventional cancer
treatments, cannabis has an outstanding safety profile, and
patients in states with medical marijuana laws are able to make an
informed decision to legally try various cannabis preparations to
determine what is most effective for their particular
condition.
Some of these scientifically informed patients have chosen to
self-administer Cannabis Science extracts supplied by Rockbrook to
treat their own cancers. Cannabis Science is delighted that
patients are reporting dramatic improvements in their conditions,
including basal cell carcinoma, non-small cell lung cancer
accompanied by COPD (chronic obstructive pulmonary disease),
ovarian cancer, and glioma.
Please visit www.cannabisscience.com to view the “Breaking News”
of the successful results and images of the self-administered
cancer treatments.
For example, a patient with basal cell carcinoma used a topical
formulation to dramatically and rapidly eliminate her obvious skin
cancer. Meanwhile, patients with internal tumors used oral
formulations for their treatment. We currently await more complete
clinical evaluations of the patients’ own reports of dramatic
health improvements coincident with tumor shrinkage and
disappearance.
Dr. Robert J. Melamede, the CEO and President of Cannabis
Science Inc., stated, "We will pursue and acquire intra-state
generated data to make these cancer medicines available to the
public at large as rapidly as possible. To accomplish this goal, we
will seek accelerated FDA approval. We are on the verge of a
revolution in medicine. Cannabis is now returning to modern
medicine for all the right reasons. State generated results give us
a unique ability to acquire scientific and clinical data for
cannabis-based cancer treatments. As previously announced, we will
use our new laboratory facility to house analytical
instrumentation, tissue culture, clean rooms and additional
necessary equipment. This facility will meet or exceed all federal,
state, and local requirements to allow for the necessary for FDA
clinical trials.”
Cannabis Science expects to hold a press conference soon to
formally announce its cancer formulation progress and future plans
for cancer treatments. Brand names for our new cancer
treatment drugs are currently being vetted through the company
attorney for future commercial use.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The Company works
with world authorities on phytocannabinoid science targeting
critical illnesses, and adheres to scientific methodologies to
develop, produce and commercialize phytocannabinoid-based
pharmaceutical products. In sum, we are dedicated to the creation
of cannabis-based medicines, both with and without psychoactive
properties, to treat disease and the symptoms of disease, as well
as for general health maintenance.
Forward Looking Statements; This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing works such as "anticipate," "seek,"
intend," "believe," "plan," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science, Inc.
does not undertake any duty nor does it intend to update the
results of these forward-looking statements.